Publication

Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo

Rozenbaum, R. T., Su, L., Umerska, A., Eveillard, M., Hakansson, J., Mahlapuu, M., Huang, F., Liu, J., Zhang, Z., Shi, L., van der Mei, H. C., Busscher, H. J. & Sharma, P. K., 10-Jan-2019, In : Journal of Controlled Release. 293, p. 73-83 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Rozenbaum, R. T., Su, L., Umerska, A., Eveillard, M., Hakansson, J., Mahlapuu, M., Huang, F., Liu, J., Zhang, Z., Shi, L., van der Mei, H. C., Busscher, H. J., & Sharma, P. K. (2019). Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo. Journal of Controlled Release, 293, 73-83. https://doi.org/10.1016/j.jconrel.2018.11.018

Author

Rozenbaum, Rene T. ; Su, Linzhu ; Umerska, Anita ; Eveillard, Matthieu ; Hakansson, Joakim ; Mahlapuu, Margit ; Huang, Fan ; Liu, Jianfeng ; Zhang, Zhenkun ; Shi, Linqi ; van der Mei, Henny C. ; Busscher, Henk J. ; Sharma, Prashant K. / Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo. In: Journal of Controlled Release. 2019 ; Vol. 293. pp. 73-83.

Harvard

Rozenbaum, RT, Su, L, Umerska, A, Eveillard, M, Hakansson, J, Mahlapuu, M, Huang, F, Liu, J, Zhang, Z, Shi, L, van der Mei, HC, Busscher, HJ & Sharma, PK 2019, 'Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo', Journal of Controlled Release, vol. 293, pp. 73-83. https://doi.org/10.1016/j.jconrel.2018.11.018

Standard

Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo. / Rozenbaum, Rene T.; Su, Linzhu; Umerska, Anita; Eveillard, Matthieu; Hakansson, Joakim; Mahlapuu, Margit; Huang, Fan; Liu, Jianfeng; Zhang, Zhenkun; Shi, Linqi; van der Mei, Henny C.; Busscher, Henk J.; Sharma, Prashant K.

In: Journal of Controlled Release, Vol. 293, 10.01.2019, p. 73-83.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Rozenbaum RT, Su L, Umerska A, Eveillard M, Hakansson J, Mahlapuu M et al. Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo. Journal of Controlled Release. 2019 Jan 10;293:73-83. https://doi.org/10.1016/j.jconrel.2018.11.018


BibTeX

@article{b2983c47f9ce4696a81ccd3065ccaf81,
title = "Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo",
abstract = "Bacterial infections are mostly due to bacteria in their biofilm-mode of growth, while penetrability of anti-microbials into infectious biofilms and increasing antibiotic resistance hamper infection treatment. In-vitro, monolaurin lipid nanocapsules (ML-LNCs) carrying adsorbed antimicrobial peptides (AMPs) displayed synergistic efficacy against planktonic Staphylococcus aureus, but it has not been demonstrated, neither in-vitro nor in-vivo, that such ML-LNCs penetrate into infectious S. aureus biofilms and maintain synergy with AMPs. This study investigates the release mechanism of AMPs from ML-LNCs and possible antimicrobial synergy of ML-LNCs with the AMPs DPK-060 and LL-37 against S. aureus biofilms in-vitro and in a therapeutic, murine, infected wound-healing model. Zeta potentials demonstrated that AMP release from ML-LNCs was controlled by the AMP concentration in suspension. Both AMPs demonstrated no antimicrobial efficacy against four staphylococcal strains in a planktonic mode, while a checkerboard assay showed synergistic antimicrobial efficacy when ML-LNCs and DPK-060 were combined, but not for combinations of ML-LNCs and LL-37. Similar effects were seen for growth reduction of staphylococcal biofilms, with antimicrobial synergy persisting only for ML-LNCs at the highest level of DPK-060 or LL-37 adsorption. Healing of wounds infected with bioluminescent S. aureus Xen36, treated with ML-LNCs alone, was faster when treated with PBS, while AMPs alone did not yield faster wound-healing than PBS. Faster, synergistic wound-healing due to ML-LNCs with adsorbed DPK-060, was absent in-vivo. Summarizing, antimicrobial synergy of ML-LNCs with adsorbed antimicrobial peptides as seen in-vitro, is absent in in-vivo healing of infected wounds, likely because host AMPs adapted the synergistic role of the AMPs added. Thus, conclusions regarding synergistic antimicrobial efficacy, should not be drawn from planktonic data, while even in-vitro biofilm data bear little relevance for the in-vivo situation.",
keywords = "Monolaurin, Antimicrobial peptides, Nanocapsules, Zeta potentials, Biofilms, Wound-healing, BACTERIAL-RESISTANCE, ESSENTIAL OILS, COMPONENTS, INFECTION, DELIVERY, SURFACE, MODELS, LL-37",
author = "Rozenbaum, {Rene T.} and Linzhu Su and Anita Umerska and Matthieu Eveillard and Joakim Hakansson and Margit Mahlapuu and Fan Huang and Jianfeng Liu and Zhenkun Zhang and Linqi Shi and {van der Mei}, {Henny C.} and Busscher, {Henk J.} and Sharma, {Prashant K.}",
year = "2019",
month = jan,
day = "10",
doi = "10.1016/j.jconrel.2018.11.018",
language = "English",
volume = "293",
pages = "73--83",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier Bedrijfsinformatie b.v.",

}

RIS

TY - JOUR

T1 - Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo

AU - Rozenbaum, Rene T.

AU - Su, Linzhu

AU - Umerska, Anita

AU - Eveillard, Matthieu

AU - Hakansson, Joakim

AU - Mahlapuu, Margit

AU - Huang, Fan

AU - Liu, Jianfeng

AU - Zhang, Zhenkun

AU - Shi, Linqi

AU - van der Mei, Henny C.

AU - Busscher, Henk J.

AU - Sharma, Prashant K.

PY - 2019/1/10

Y1 - 2019/1/10

N2 - Bacterial infections are mostly due to bacteria in their biofilm-mode of growth, while penetrability of anti-microbials into infectious biofilms and increasing antibiotic resistance hamper infection treatment. In-vitro, monolaurin lipid nanocapsules (ML-LNCs) carrying adsorbed antimicrobial peptides (AMPs) displayed synergistic efficacy against planktonic Staphylococcus aureus, but it has not been demonstrated, neither in-vitro nor in-vivo, that such ML-LNCs penetrate into infectious S. aureus biofilms and maintain synergy with AMPs. This study investigates the release mechanism of AMPs from ML-LNCs and possible antimicrobial synergy of ML-LNCs with the AMPs DPK-060 and LL-37 against S. aureus biofilms in-vitro and in a therapeutic, murine, infected wound-healing model. Zeta potentials demonstrated that AMP release from ML-LNCs was controlled by the AMP concentration in suspension. Both AMPs demonstrated no antimicrobial efficacy against four staphylococcal strains in a planktonic mode, while a checkerboard assay showed synergistic antimicrobial efficacy when ML-LNCs and DPK-060 were combined, but not for combinations of ML-LNCs and LL-37. Similar effects were seen for growth reduction of staphylococcal biofilms, with antimicrobial synergy persisting only for ML-LNCs at the highest level of DPK-060 or LL-37 adsorption. Healing of wounds infected with bioluminescent S. aureus Xen36, treated with ML-LNCs alone, was faster when treated with PBS, while AMPs alone did not yield faster wound-healing than PBS. Faster, synergistic wound-healing due to ML-LNCs with adsorbed DPK-060, was absent in-vivo. Summarizing, antimicrobial synergy of ML-LNCs with adsorbed antimicrobial peptides as seen in-vitro, is absent in in-vivo healing of infected wounds, likely because host AMPs adapted the synergistic role of the AMPs added. Thus, conclusions regarding synergistic antimicrobial efficacy, should not be drawn from planktonic data, while even in-vitro biofilm data bear little relevance for the in-vivo situation.

AB - Bacterial infections are mostly due to bacteria in their biofilm-mode of growth, while penetrability of anti-microbials into infectious biofilms and increasing antibiotic resistance hamper infection treatment. In-vitro, monolaurin lipid nanocapsules (ML-LNCs) carrying adsorbed antimicrobial peptides (AMPs) displayed synergistic efficacy against planktonic Staphylococcus aureus, but it has not been demonstrated, neither in-vitro nor in-vivo, that such ML-LNCs penetrate into infectious S. aureus biofilms and maintain synergy with AMPs. This study investigates the release mechanism of AMPs from ML-LNCs and possible antimicrobial synergy of ML-LNCs with the AMPs DPK-060 and LL-37 against S. aureus biofilms in-vitro and in a therapeutic, murine, infected wound-healing model. Zeta potentials demonstrated that AMP release from ML-LNCs was controlled by the AMP concentration in suspension. Both AMPs demonstrated no antimicrobial efficacy against four staphylococcal strains in a planktonic mode, while a checkerboard assay showed synergistic antimicrobial efficacy when ML-LNCs and DPK-060 were combined, but not for combinations of ML-LNCs and LL-37. Similar effects were seen for growth reduction of staphylococcal biofilms, with antimicrobial synergy persisting only for ML-LNCs at the highest level of DPK-060 or LL-37 adsorption. Healing of wounds infected with bioluminescent S. aureus Xen36, treated with ML-LNCs alone, was faster when treated with PBS, while AMPs alone did not yield faster wound-healing than PBS. Faster, synergistic wound-healing due to ML-LNCs with adsorbed DPK-060, was absent in-vivo. Summarizing, antimicrobial synergy of ML-LNCs with adsorbed antimicrobial peptides as seen in-vitro, is absent in in-vivo healing of infected wounds, likely because host AMPs adapted the synergistic role of the AMPs added. Thus, conclusions regarding synergistic antimicrobial efficacy, should not be drawn from planktonic data, while even in-vitro biofilm data bear little relevance for the in-vivo situation.

KW - Monolaurin

KW - Antimicrobial peptides

KW - Nanocapsules

KW - Zeta potentials

KW - Biofilms

KW - Wound-healing

KW - BACTERIAL-RESISTANCE

KW - ESSENTIAL OILS

KW - COMPONENTS

KW - INFECTION

KW - DELIVERY

KW - SURFACE

KW - MODELS

KW - LL-37

U2 - 10.1016/j.jconrel.2018.11.018

DO - 10.1016/j.jconrel.2018.11.018

M3 - Article

VL - 293

SP - 73

EP - 83

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -

ID: 91671557